IL33 and lung carcinoma: Primary lung carcinoma cells, TC1, treated with IL-33-directed siRNAs had a much lower abundance of MHC-I complexes than did controls (Fig. 2c), whereas the overexpression of IL-33 in metastatic cells (A9) (Fig. 2b) had a higher level of MHC-I production compared to untransfected controls (Fig. 2d).